Immune correlates of the differing pathological and therapeutic effects of neoadjuvant chemotherapy in breast cancer

Conclusions: Increased NK cells after NAC, together with increased CD4+ and CD8+ T-cells, and decreased CTLA-4+ T cells and VEGF correlate with beneficial therapeutic effects. Systemic activation of pNK cell activity and the presence of pre-NAC TILs may improve the elimination of Ax + together with decreased immunosuppression by VEGF in tumors.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research

Related Links:

Increasing numbers of breast cancer patients receive neoadjuvant chemotherapy (NACT). We seek to investigate whether baseline mammographic and ultrasound features are associated with complete pathological resp...
Source: Cancer Imaging - Category: Radiology Authors: Tags: Research article Source Type: research
Conditions:   Breast Cancer;   Drug Effect Intervention:   Sponsors:   Peking University People's Hospital;   Peking University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsWomen who received NET had similar rates of BCS compared to women who received NAC. Those who received NET for longer treatment durations had increased odds of BCS and downstaging compared to women who did not receive neoadjuvant therapy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conclusions: The combination of NLR and PLR showed improved prediction of NAC response, revealing their potential as screening tools, significant prognostic role in breast cancer patients who receive NAC. Further studies with subgroup analysis, larger population and longer follow up duration are required. PMID: 31598342 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Conclusion: Despite the low pCR rate, the tumor response and BCS conversion rates after NAC of luminal HER2- breast cancer were similar to those of other subtypes. NAC has the potential benefit of reducing the size of breast cancer, thereby increasing the BCS conversion rate in luminal HER2- breast cancer. PMID: 31598341 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
This study was aimed at identifying the influence of initial weight and weight change during neoadjuvant chemotherapy (NAC) on pathologic complete response (pCR) and long-term survival in Chinese patients with operable breast cancer. Methods: We conducted a retrospective study using data from 409 female patients who received NAC for stage II or III breast cancer and had complete record of body mass index (BMI) before and after NAC. BMI of 2 kg/m2 following NAC was considered to be significant, else was considered stable. The study end points included pCR rates, disease-free survival (DFS), and overall survival (OS). ...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: The pre-treatment tumor SUVmax could be utilized as an independent imaging biomarker of the tumor aggressiveness and poor prognosis. Risk stratification based on this index could play a pivotal role in alteration of treatment planning, such as neoadjuvant chemotherapy (precision oncology). PMID: 31587025 [PubMed - as supplied by publisher]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
ConclusionsMRI demonstrated good accuracy in predicting pCR after NAC among the breast cancer patients examined. However, non-mass enhancement at pre-treatment MRI negatively affected the diagnostic performance of MRI in assessing treatment response after NAC.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Publication date: November 2019Source: European Journal of Surgical Oncology, Volume 45, Issue 11Author(s): Aaliya Uddin, Wayne Chicken, Mohamed Elamass, Firas Alkistawi, Smita Singh, Abdalla Saad Abdalla Al-zawi
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Surgery